KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivchev, Carsten Utoft Niemann, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Beenish S Manzoor, Dureshahwar Jawaid, Nnadozie Emechebe, Jacob Devine, Michelle Boyer, Eva D Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

Blood 144(18) 1924-1935

PMID39082668
PMCIDPMC11551846
DOI10.1182/blood.2024024631
发表日期2024-07-31
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

In the CLL14 study, patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions were randomized to 12 cycles of venetoclax-obinutuzumab (Ven-Obi, n = 216) or chlorambucil-obinutuzumab (Clb-Obi, n = 216). Progression-free survival (PFS) was the primary end point. Key secondary end points included time-to-next-treatment (TTNT), rates of undetectable minimal residual disease (uMRD), overall survival (OS), and rates of adverse events. Patient reported outcomes of time until definitive deterioration (TUDD) in quality of life (QoL) were analyzed. At a median observation time of 76.4 months, PFS remained superior for Ven-Obi compared with Clb-Obi (median, 76.2 vs 36.4 months; hazard ratio [HR], 0.40; 95% confidence interval [CI], 0.31-0.52; P < .0001). Likewise, TTNT was longer after Ven-Obi (6-year TTNT, 65.2% vs 37.1%; HR, 0.44; 95% CI, 0.33-0.58; P < .0001). In the Ven-Obi arm, presence of del(17p), unmutated immunoglobulin heavy-chain variable region, and lymph node size of ≥5 cm were independent prognostic factors for shorter PFS. The 6-year OS rate was 78.7% in the Ven-Obi and 69.2% in the Clb-Obi arm (HR, 0.69; 95% CI, 0.48-1.01; P = .052). A significantly longer TUDD in global health status/QoL was observed in the Ven-Obi than in the Clb-Obi arm (median, 82.1 vs 65.1 months; HR, 0.70; 95% CI, 0.51-0.97). Follow-up-adjusted second primary malignancies incidence rates were 2.3 and 1.4 per 1000 patient-months in the Ven-Obi and Clb-Obi arm, respectively. The sustained long-term survival and QoL benefits support the use of 1-year fixed-duration Ven-Obi in CLL. This trial was registered at www.ClinicalTrials.gov as #NCT02242942.

KM 提取结果

2 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

Progression-free_survival

PFS

Figure 1 · Panel Progression-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Progression-free_survival 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Overall_survival

OS

Figure 1 · Panel Overall_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_survival 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
KM Figure4 个面板

Figure 4.

TTNT and second primary malignancy incidence. (A) TTNT, defined as time to initiation of next line of antileukemic treatment or death from any cause, according to Ven-Obi (blue) or Clb-Obi (red) arm. (B) TTNT according to presence (solid line) or absence (dashed line) of TP53 deletion/mutation. (C) TTNT according to mutated- (solid line) and unmutated- (dashed line) IGHV status. (D) Cumulative incidence of SPM according to Ven-Obi (blue) and Clb-Obi (red) arm.

A

TTNT

Figure 4. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

TTNT

Figure 4. · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

TTNT

Figure 4. · Panel C

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel C 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:off origin start曲线 4:extreme upward reversal
查看结果
D

SPM

Figure 4. · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.PFS. (A) PFS according to Ven-Obi (blue) and Clb-Obi (red) arm. (B) PFS according to presence (solid line) or absence (dashed line) of TP53 deletion/mutation. (C) PFS according to mutated- (solid line) or unmutated- (dashed line) IGHV status. (D) Multivariable models for PFS for the Ven-Obi (upper panel) and Clb-Obi arm (lower panel). del/mut, deletion and/or mutation; mIGHV, mutated IGHV; uIGHV, unmutated IGHV.
非 KM Figure
Figure 2.OS. (A) OS according to Ven-Obi (blue) and Clb-Obi (red) arm. (B) OS according to presence (solid line) or absence (dashed line) of TP53 deletion/mutation. (C) OS according to mutated- (solid line) or unmutated- (dashed line) IGHV status. (D) Multivariable models for OS for the Ven-Obi (upper panel) and Clb-Obi arm (lower panel). ECOG, Eastern Cooperative Oncology Group. mIGHV, mutated IGHV; uIGHV unmutated IGHV; del/mut, deletion and/or mutation.
非 KM Figure
Figure 3.MRD. (A) MRD assessments in the peripheral blood by next-generation sequencing in the Ven-Obi arm. (B) MRD assessments in the peripheral blood by next-generation sequencing in the Clb-Obi arm. (C) Landmark PFS analysis according to MRD status in the Ven-Obi arm. (D) Landmark PFS analysis according to MRD status in the Clb-Obi arm.
非 KM Figure